Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial

Abstract Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelim...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, Maria Plana Serrahima, Miren Taberna Sanz, Beatriz Castelo, Cristina Álvarez-Escolá, Alberto Carmona-Bayonas, Inmaculada Ballester Navarro, Lara Iglesias, Mateo Bover, Alejandro Garcia-Alvarez, Javier Lavernia, Ricardo Yayá Tur, Sofia Ruiz, Neus Baste, Isabel Lorenzo-Lorenzo, Alfredo Sanchez-Hernandez, Enrique Sanz-Garcia, Gloria Marquina, Paolo Nuciforo, Belén Elguero, Enrique Grande, Teresa Alonso-Gordoa
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Nature Portfolio 2026-04-01
Ráidu:	Nature Communications
Liŋkkat:	https://doi.org/10.1038/s41467-026-71155-y
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!